アロプリノールと痛風性高尿血症. 1日1回投与の有効性について

G P Rodnan, J A Robin, S F Tolchin

JAMA

|March 17, 1975

まとめ

アロプリノールの1日300mgの投与は,痛風患者の血清尿酸濃度を効果的に低下させます. このレジミンは,分割された投与量と同じくらい効果があり,高尿血症の治療を簡素化します.

科学分野:

薬理学薬理学とは
レウマトロジーの病理学
クリニカル・メディシン臨床医学

背景:

ハイパーウリケミアと痛風は,血清尿酸濃度の上昇と関連しています.
アロプリノールは,尿酸の産生を減らすための一般的な治療法です.

研究の目的:

ハイパーウリケミアの管理におけるアルロプリノールの1日1回の投与と分割された投与の有効性を比較する.
血清ウラートおよびオキシプリノール濃度への影響を評価する.

主な方法:

オープンラベルのクロスオーバー試験で,高尿血症と痛風の患者20人が参加した.
患者は,アルロピュリノールの単一の300mg錠剤または分割された用量 (100mg TID) を受けました.
血清ウラートおよびオキシプリノール濃度もモニタリングされた.

主要な成果:

両方の治療法は血清ウラート濃度の急速な低下をもたらした.
アロピュリノールの1日1回投与と分割投与の間に有意な差異は認められませんでした.
血清オキシピュリノールの最低濃度も,グループ間の有意な差異を示さなかった.

結論:

アロプリノールの1回300mgの投与量は,痛風患者の血清尿酸値を下げるのに有効で便利な選択肢です.
この簡素化された投与法は,従来の分割された投与量と同等の有効性を提供します.
この発見は,痛風性高尿性血症の管理のために1日1回アルロプリノールの使用を支持する.

さらに関連する動画

04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

関連する概念動画

01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...

01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...

01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).

01:30

Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care

A healthcare provider can diagnose a urinary tract infection (UTI) through several methods:Medical History and Symptoms: The provider will take a detailed medical history and ask about symptoms such as frequent urination, burning sensation during urination, and lower abdominal pain.Urinalysis: A clean-catch urine sample is collected in a sterile container and tested for the presence of bacteria, white blood cells (leukocytes), nitrites, blood, and protein. The presence of leukocytes and...

関連する実験動画